Onatasertib re-sensitizes refractory nasopharyngeal carcinoma to immunotherapy: a Case Report
Frontiers in Pharmacology · 17.07.2026 · 17
DOI: 10.3389/fphar.2026.1614224 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 17.07.2026. Verfasst von Peipei Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hubei Minzu University Affiliated Enshi Clinical Medical School, the Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, China. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The standard first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC) is currently a combination of a programmed cell death protein-1 (PD-1) blockade and gemcitabine-cisplatin. However, effective options beyond second-line settings are limited, and a recommended regimen is currently unavailable. This report presents a case study highlighting the significant efficacy of onatasertib, a dual mechanistic target of rapamycin (mTOR) 1/2 inhibitor, in overcoming resistance to immunotherapy in patients with R/M-NPC. A 28-year-old female patient who was diagnosed with nasopharyngeal carcinoma (NPC) experienced tumor relapse following progression on multiple lines of therapy, including immunotherapy. Subsequently, the patient participated in a phase I/II study (TORCH-2) investigating the combination of onatasertib and toripalimab in patients with advanced solid tumors. The patient achieved a nearly complete remission (CR) and experienced a progression-free survival (PFS) of 16 months. This unique case report highlights the efficacy of onatasertib, a dual mTOR1/2 inhibitor, in treating patients with R/M-NPC who have developed resistance to immunotherapy. The occurrence of a grade 2 serious adverse event (AE) underscores the importance of monitoring patients closely during treatment and the need to adjust dosages when necessary to minimize AEs. Meanwhile, it is important to note that the small sample size in this case is a significant limitation. Therefore, further randomized clinical trials are required to evaluate the efficacy and safety of this combination treatment in patients with acquired immunotherapy resistance and R/M-NPC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hubei Minzu University Affiliated Enshi Clinical Medical School, the Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, China.
- Hubei Provincial Key Lab of Selenium Resources and Bioapplications, Enshi, China.
- Hubei Selenium and Human Health Institute, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, China.
- Cancer Center, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, China.
- College of Biological and Food Engineering, Hubei Minzu University, Enshi, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, P., Zhang, Z., Liu, J., Cui, Y., Qin, D., Lai, L., Xiang, Y., Wang, L., Li, D., Luo, K., & Huang, C. (2026). Onatasertib re-sensitizes refractory nasopharyngeal carcinoma to immunotherapy: a Case Report. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1614224
Vancouver
Zhang P, Zhang Z, Liu J, Cui Y, Qin D, Lai L, et al. Onatasertib re-sensitizes refractory nasopharyngeal carcinoma to immunotherapy: a Case Report. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1614224
BibTeX
@article{Zhang2026,
author = {Zhang, Peipei and Zhang, Zhanpeng and Liu, Jun and Cui, Yanfei and Qin, Daming and Lai, Lin and Xiang, Ying and Wang, Li and Li, Dezhong and Luo, Kai and Huang, Chuying},
title = {Onatasertib re-sensitizes refractory nasopharyngeal carcinoma to immunotherapy: a Case Report},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1614224}
}
EUVIMED